600572 康恩贝
已收盘 06-18 15:00:00
资讯
新帖
简况
每周股票复盘:康恩贝(600572)每股派息0.15元,行权价下调
证券之星 · 06-20 03:09
每周股票复盘:康恩贝(600572)每股派息0.15元,行权价下调
康恩贝:截至2026年6月10日,公司股东总户数为92,684户
证券之星 · 06-18
康恩贝:截至2026年6月10日,公司股东总户数为92,684户
康恩贝:公司已制订并经董事会审议通过康恩贝“十五五”战略规划
证券之星 · 06-18
康恩贝:公司已制订并经董事会审议通过康恩贝“十五五”战略规划
康恩贝:珍视明公司已完成股份制改造
证券之星 · 06-18
康恩贝:珍视明公司已完成股份制改造
康恩贝(600572)披露关于调整2022年股票期权激励计划的股票期权行权价格的公告,6月17日股价下跌0.24%
证券之星 · 06-17
康恩贝(600572)披露关于调整2022年股票期权激励计划的股票期权行权价格的公告,6月17日股价下跌0.24%
康恩贝:前次于2024年7月完成回购公司股份6,357.9048万股
证券之星 · 06-17
康恩贝:前次于2024年7月完成回购公司股份6,357.9048万股
康恩贝:6月10日收盘后股东总户数为92,684户
证券之星 · 06-17
康恩贝:6月10日收盘后股东总户数为92,684户
康恩贝(600572)披露2025年年度权益分派实施公告,6月16日股价下跌0.72%
证券之星 · 06-16
康恩贝(600572)披露2025年年度权益分派实施公告,6月16日股价下跌0.72%
康恩贝(600572.SH)拟不低于4978.27万元挂牌转让东阳康恩贝100%股权
智通财经 · 06-08
康恩贝(600572.SH)拟不低于4978.27万元挂牌转让东阳康恩贝100%股权
每周股票复盘:康恩贝(600572)2025年年度股东会顺利召开
证券之星 · 05-17
每周股票复盘:康恩贝(600572)2025年年度股东会顺利召开
康恩贝(600572)披露2025年年度股东会法律意见书,5月13日股价上涨0.23%
证券之星 · 05-13
康恩贝(600572)披露2025年年度股东会法律意见书,5月13日股价上涨0.23%
每周股票复盘:康恩贝(600572)拟每10股派1.50元
证券之星 · 05-10
每周股票复盘:康恩贝(600572)拟每10股派1.50元
康恩贝(600572.SH)子公司布南色林片获得药品注册证书
智通财经 · 05-08
康恩贝(600572.SH)子公司布南色林片获得药品注册证书
每周股票复盘:康恩贝(600572)2026年一季度营收增13.1%
证券之星 · 04-26
每周股票复盘:康恩贝(600572)2026年一季度营收增13.1%
康恩贝(600572)披露2025年年度报告,4月23日股价下跌1.96%
证券之星 · 04-23
康恩贝(600572)披露2025年年度报告,4月23日股价下跌1.96%
图解康恩贝年报:第四季度单季净利润同比下降205.49%
证券之星 · 04-23
图解康恩贝年报:第四季度单季净利润同比下降205.49%
股市必读:康恩贝(600572)4月17日收盘跌5.26%,主力净流出666.26万元
证券之星 · 04-20
股市必读:康恩贝(600572)4月17日收盘跌5.26%,主力净流出666.26万元
每周股票复盘:康恩贝(600572)因股价涨幅偏离值达7%登龙虎榜
证券之星 · 04-19
每周股票复盘:康恩贝(600572)因股价涨幅偏离值达7%登龙虎榜
4月15日康恩贝(600572)龙虎榜数据:北向资金净卖出3528.59万元
证券之星 · 04-15
4月15日康恩贝(600572)龙虎榜数据:北向资金净卖出3528.59万元
国办一纸文件定调药价,创新药爆发!涨停名单还在拉长
格隆汇 · 04-15
国办一纸文件定调药价,创新药爆发!涨停名单还在拉长
暂无数据
公司概况
公司名称:
浙江康恩贝制药股份有限公司
所属行业:
医药制造业
上市日期:
2004-04-12
主营业务:
浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造与销售业务。公司的主要产品是“前列康”牌普乐安片及胶囊、“天保宁”牌银杏叶制剂、“康恩贝”牌肠炎宁系列、“金奥康”牌奥美拉唑肠溶胶囊、“金笛”牌复方鱼腥草合剂、“金艾康”牌汉防己甲素片、“金康速力”牌乙酰半胱氨酸泡腾片、“至心砃”牌麝香通心滴丸、“康恩贝”、“宝芝林”、“养营堂”品牌系列保健食品和功能性食品。公司经过逾五十年的发展,已成为国内医药行业的知名企业之一,多年来位居全国制药百强及中药企业排名前列,是国家中药现代化科技产业(浙江)基地示范企业。公司在现代植物药(含中成药)与特色化学药制剂和原料药等领域,实现了从种植、研发、生产到营销的全产业链覆盖,在消化系统、呼吸系统、心脑血管、泌尿系统等中国药品市场最具规模和成长性的治疗领域,形成了较为完善的产品品类布局。报告期内,公司位列“2024年度中国医药工业百强企业”第55位、“2025年度中国非处方药生产企业综合统计榜”第12位、“2025年度中国中成药企业综合竞争力50强”第15名。
发行价格:
8.25
{"stockData":{"symbol":"600572","market":"SH","secType":"STK","nameCN":"康恩贝","latestPrice":4.12,"timestamp":1781766002000,"preClose":4.11,"halted":0,"volume":23038741,"delay":0,"changeRate":0.0024,"floatShares":2532000000,"shares":2538000000,"eps":0.1905,"marketStatus":"已收盘","change":0.01,"latestTime":"06-18 15:00:00","open":4.11,"high":4.16,"low":4.09,"amount":95051000,"amplitude":0.017,"askPrice":4.12,"askSize":91,"bidPrice":4.11,"bidSize":7077,"shortable":0,"etf":0,"ttmEps":0.1905,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":4.11,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":4.52,"lowLimit":3.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2538482531,"isCdr":false,"pbRate":1.44,"roa":"--","peRate":21.627297,"roe":"2.77%","epsLYR":0.19,"committee":-0.081893,"marketValue":10459000000,"turnoverRate":0.0091,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-06-22。","floatMarketCap":10431000000},"requestUrl":"/m/hq/s/600572/tweets","defaultTab":"tweets","newsList":[{"id":"2644652580","title":"每周股票复盘:康恩贝(600572)每股派息0.15元,行权价下调","url":"https://stock-news.laohu8.com/highlight/detail?id=2644652580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644652580?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:09","pubTimestamp":1781896189,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,康恩贝报收于4.12元,较上周的4.13元下跌0.24%。本周,康恩贝6月15日盘中最高价报4.18元。公司公告汇总浙江康恩贝制药股份有限公司实施2025年年度权益分派,每股派发现金红利0.15元(含税),股权登记日为2026年6月23日,除权(息)日与现金红利发放日均为2026年6月24日。本次派息以总股本2,538,482,531股为基数,合计派发380,772,379.65元。本次权益分派将相应调整2022年股票期权激励计划的行权价格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000001872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","600572","BK0239","BK0012","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644670239","title":"康恩贝:截至2026年6月10日,公司股东总户数为92,684户","url":"https://stock-news.laohu8.com/highlight/detail?id=2644670239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644670239?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:12","pubTimestamp":1781777529,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝(600572)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘:您好! 麻烦您告知公司截止6月10日的股东人数,谢谢!康恩贝回复:尊敬的投资者您好!截至2026年6月10日,公司股东总户数为92,684户。感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800032533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0097","BK0012","BK0028","BK0188","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644023947","title":"康恩贝:公司已制订并经董事会审议通过康恩贝“十五五”战略规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2644023947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644023947?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:12","pubTimestamp":1781777528,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝06月18日在投资者关系平台上答复投资者关心的问题。公司已制订并经董事会审议通过康恩贝“十五五”战略规划,计划在未来的五年内,通过实施“八大专项”战略举措,实现“四个核心能力”打造,驱动康恩贝效益与价值双提升,成为受人信任尊敬的医药健康领先型企业,努力以稳健的经营成果回馈投资者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800032532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0028","BK0097","BK0188","BK0012","600572","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644023117","title":"康恩贝:珍视明公司已完成股份制改造","url":"https://stock-news.laohu8.com/highlight/detail?id=2644023117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644023117?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:12","pubTimestamp":1781777524,"startTime":"0","endTime":"0","summary":"您提及的“贵集团”为康恩贝集团有限公司,康恩贝集团现为本公司第二大股东。珍视明公司已完成股份制改造的工作,后续会根据外部监管环境和资本市场进展,择机启动IPO相关工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800032529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0188","BK0060","BK0239","BK0097","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742011","title":"康恩贝(600572)披露关于调整2022年股票期权激励计划的股票期权行权价格的公告,6月17日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742011","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644742011?lang=zh_cn&edition=full","pubTime":"2026-06-17 23:00","pubTimestamp":1781708448,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,康恩贝报收于4.11元,较前一交易日下跌0.24%,最新总市值为104.33亿元。近日,浙江康恩贝制药股份有限公司于2026年6月17日召开第十一届董事会第十八次(临时)会议,审议通过《关于调整2022年股票期权激励计划的股票期权行权价格的议案》。因公司实施2025年度权益分派方案,每10股派发现金红利1.50元(含税),根据相关规定,对公司2022年股票期权激励计划的行权价格进行调整。本次调整不影响公司财务状况和经营成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0239","BK0060","BK0028","BK0012","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644373717","title":"康恩贝:前次于2024年7月完成回购公司股份6,357.9048万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644373717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644373717?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:42","pubTimestamp":1781689341,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝(600572)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问:公司为什么不回购自家股份?这价格还算贵吗?康恩贝回复:尊敬的投资者您好!公司高度重视股东回报,前次于2024年7月完成回购公司股份6,357.9048万股,于2025年7月完成全部回购股份的注销手续,有效增厚了全体股东权益。后续,公司将结合市场情况、资金安排及股价表现等情况综合研判、审慎决策,择机通过回购公司股份等举措以维护和提升公司价值。感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700030920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0188","BK0097","BK0060","600572","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644171731","title":"康恩贝:6月10日收盘后股东总户数为92,684户","url":"https://stock-news.laohu8.com/highlight/detail?id=2644171731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644171731?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:39","pubTimestamp":1781689145,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝(600572)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘您好!请问截止6月5日收盘公司的股东人数是多少?康恩贝回复:尊敬的投资者您好!公司最近一次获取中国证券登记结算有限责任公司上海分公司的股东数据为6月10日,当日收盘后股东总户数为92,684户,供您参考。感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700030842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","600572","BK0012","BK0239","BK0060","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643561077","title":"康恩贝(600572)披露2025年年度权益分派实施公告,6月16日股价下跌0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643561077","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643561077?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:33","pubTimestamp":1781605997,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,康恩贝报收于4.12元,较前一交易日下跌0.72%,最新总市值为104.52亿元。近日,浙江康恩贝制药股份有限公司发布《2025年年度权益分派实施公告》。公告显示,本次每股派发现金红利0.15元(含税),股权登记日为2026年6月23日,除权(息)日和现金红利发放日均为2026年6月24日。分派对象为截至股权登记日在中国结算上海分公司登记在册的全体股东。本次权益分派完成后将相应调整2022年股票期权激励计划的行权价格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600034703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0012","BK0188","BK0060","600572","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641885864","title":"康恩贝(600572.SH)拟不低于4978.27万元挂牌转让东阳康恩贝100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2641885864","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641885864?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:22","pubTimestamp":1780910564,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康恩贝(600572.SH)发布公告,公司拟通过浙江产权交易所以公开挂牌方式转让所持有的东阳市康恩贝印刷包装有限公司(简称“东阳康恩贝”)100%股权,挂牌价为不低于4978.27万元。东阳康恩贝的主要客户为公司和下属子公司,市场化程度低,竞争力偏弱。此次通过公开挂牌转让东阳康恩贝100%股权,退出与公司核心发展战略关联弱、回报率低的领域,不仅能直接回收现金、补充营运资金,更能“做减法”,消除管理冗余,将资源配置到核心的药品研发、管线拓展、品牌建设与市场深耕上,强化主营主业的竞争壁垒,确保公司在中医药大健康赛道实现更高质量、更可持续的发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0188","BK0239","BK0097","BK0028","BK0060","600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636206231","title":"每周股票复盘:康恩贝(600572)2025年年度股东会顺利召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2636206231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636206231?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:11","pubTimestamp":1778962270,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:康恩贝2025年年度股东会于2026年5月13日召开,审议通过多项议案。公司公告汇总北京观韬(杭州)律师事务所对公司2025年年度股东会的召集和召开程序、出席会议人员资格、召集人资格、表决程序及表决结果等事项出具法律意见。浙江康恩贝制药股份有限公司于2026年5月13日召开2025年年度股东会,会议由董事会召集,董事长应徐颉主持,采用现场与网络投票相结合方式召开,表决程序合法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0012","BK0188","BK0239","BK0028","BK0060","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635382735","title":"康恩贝(600572)披露2025年年度股东会法律意见书,5月13日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635382735","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635382735?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:37","pubTimestamp":1778683036,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘,康恩贝报收于4.41元,较前一交易日上涨0.23%,最新总市值为111.88亿元。该股当日开盘4.41元,最高4.41元,最低4.38元,成交额达1.74亿元,换手率为1.56%。近日,康恩贝发布关于2025年年度股东会的法律意见书。北京观韬(杭州)律师事务所对公司2025年年度股东会的召集和召开程序、出席会议人员资格、召集人资格、表决程序及表决结果等事项出具法律意见。表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300045870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0188","BK0060","BK0012","BK0239","BK0028","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634841480","title":"每周股票复盘:康恩贝(600572)拟每10股派1.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634841480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634841480?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:10","pubTimestamp":1778350220,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,康恩贝报收于4.41元,较上周的4.48元下跌1.56%。本周,康恩贝5月6日盘中最高价报4.49元。康恩贝当前最新总市值111.88亿元,在中药板块市值排名19/66,在两市A股市值排名1903/5200。2025年实现营业收入64.73亿元,归属于上市公司股东的净利润4.74亿元。公司拟每10股派发现金红利1.50元(含税)。将继续为13家子公司提供合计18.7亿元担保额度,开展不超过15亿元票据池业务,续聘容诚会计师事务所为2026年度财务审计机构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0188","BK0239","BK0097","BK0028","BK0060","600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633436250","title":"康恩贝(600572.SH)子公司布南色林片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2633436250","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633436250?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:06","pubTimestamp":1778231194,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康恩贝(600572.SH)发布公告,近日,公司全资子公司浙江金华康恩贝生物制药有限公司(简称“金华康恩贝”)收到国家药品监督管理局核准签发的布南色林片《药品注册证书》。布南色林片由日本住友制药株式会社研发,于2008年1月获批在日本上市。原研药布南色林片(商品名:Lonasen®)于2018年2月获批在中国上市。布南色林属于5-羟色胺和多巴胺受体拮抗剂,是一种第二代新型抗精神病药,临床用于治疗精神分裂症。通过拮抗中脑边缘系统DA的D2受体和5-HT(5-羟色胺)的2A受体达到治疗精神分裂症阳性症状的目的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0188","BK0097","BK0060","600572","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804806","title":"每周股票复盘:康恩贝(600572)2026年一季度营收增13.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804806","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804806?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:20","pubTimestamp":1777144822,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,康恩贝报收于4.53元,较上周的4.68元下跌3.21%。本周,康恩贝4月20日盘中最高价报4.72元。本周关注点来自业绩披露要点:康恩贝2026年一季度主营收入19.06亿元,同比上升13.1%。业绩披露要点财务报告康恩贝2026年一季报显示,公司一季度主营收入19.06亿元,同比上升13.1%;归母净利润1.98亿元,同比上升4.78%;扣非净利润2.09亿元,同比上升28.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629388471","title":"康恩贝(600572)披露2025年年度报告,4月23日股价下跌1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629388471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629388471?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:41","pubTimestamp":1776937287,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘,康恩贝报收于4.51元,较前一交易日下跌1.96%,最新总市值为114.42亿元。该股当日开盘4.57元,最高4.57元,最低4.49元,成交额达4.03亿元,换手率为3.52%。公司于2026年4月23日披露《浙江康恩贝制药股份有限公司2025年年度报告》。公告显示,公司2025年实现营业收入6,473,433,792.42元,同比下降0.64%;利润总额645,168,572.32元,同比下降17.28%;归属于上市公司股东的净利润474,363,102.69元,同比下降23.79%;归属于上市公司股东的扣除非经常性损益的净利润373,334,542.35元,同比下降27.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300048942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0188","BK0239","BK0097","BK0028","BK0060","600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629702962","title":"图解康恩贝年报:第四季度单季净利润同比下降205.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629702962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629702962?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:02","pubTimestamp":1776877322,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝2025年年报显示,当年度公司主营收入64.73亿元,同比下降0.64%;归母净利润4.74亿元,同比下降23.79%;扣非净利润3.73亿元,同比下降27.67%;其中2025年第四季度,公司单季度主营收入14.98亿元,同比下降6.51%;单季度归母净利润-1.1亿元,同比下降205.49%;单季度扣非净利润-5774.94万元,同比下降162.83%;负债率28.37%,投资收益7801.12万元,财务费用-670.27万元,毛利率53.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300002071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628195795","title":"股市必读:康恩贝(600572)4月17日收盘跌5.26%,主力净流出666.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628195795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628195795?lang=zh_cn&edition=full","pubTime":"2026-04-20 04:18","pubTimestamp":1776629889,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,康恩贝报收于4.68元,下跌5.26%,换手率8.38%,成交量211.96万手,成交额9.93亿元。当日关注点来自交易信息汇总:4月17日康恩贝股价跌5.26%,主力资金净流出666.26万元,但游资积极介入,净流入3297.61万元。前10个交易日主力资金累计净流入1.18亿元,股价累计上涨1.65%;融资余额累计增加1.2亿元,融券余量累计减少15.96万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000001328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0188","BK0097","BK0012","600572","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628759483","title":"每周股票复盘:康恩贝(600572)因股价涨幅偏离值达7%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628759483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628759483?lang=zh_cn&edition=full","pubTime":"2026-04-19 02:57","pubTimestamp":1776538627,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,康恩贝报收于4.68元,较上周的4.42元上涨5.88%。本周,康恩贝4月16日盘中最高价报5.17元,股价触及近一年最高点。本周关注点交易信息汇总:康恩贝因日收盘价格涨幅偏离值达到7%登上龙虎榜交易信息汇总:此次为近5个交易日内第1次上榜交易信息汇总沪深交易所2026年4月15日公布的交易公开信息显示,康恩贝因有价格涨跌幅限制的日收盘价格涨幅偏离值达到7%的前五只证券登上龙虎榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0097","BK0060","BK0239","BK0012","600572","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627400322","title":"4月15日康恩贝(600572)龙虎榜数据:北向资金净卖出3528.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627400322","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627400322?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:21","pubTimestamp":1776244875,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月15日公布的交易公开信息显示,康恩贝因有价格涨跌幅限制的日收盘价格涨幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月15日收盘,康恩贝报收于4.8元,上涨10.09%,涨停,换手率8.2%,成交量207.49万手,成交额9.66亿元。从龙虎榜公布的当日买卖数据来看,北向资金合计净卖出3528.59万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0028","600572","BK0060","BK0239","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价,创新药爆发!涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"sg","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["002038","159992","06990","BK0097","BK0077","600488","BK0012","BK0188","BK0250","BK0060","02162","BK0185","BK0122","BK0197","BK0239","000919","600267","BK0028","002589","BK0132","LU0196878994.USD","06978","000788","BK1583","BK1587","BK0070","BK1161","BK0209","BK0102","BK1574","BK0096","600572","301408"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782043236713,"stockEarnings":[{"period":"1week","weight":0.0123},{"period":"1month","weight":-0.0374},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.1159},{"period":"1year","weight":-0.0452},{"period":"ytd","weight":-0.0762}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江康恩贝制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"92684人(较上一季度减少7.50%)","perCapita":"27315股","listingDate":"2004-04-12","address":"浙江省金华市兰溪市康恩贝大道1号","registeredCapital":"253848万元","survey":" 浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造与销售业务。公司的主要产品是“前列康”牌普乐安片及胶囊、“天保宁”牌银杏叶制剂、“康恩贝”牌肠炎宁系列、“金奥康”牌奥美拉唑肠溶胶囊、“金笛”牌复方鱼腥草合剂、“金艾康”牌汉防己甲素片、“金康速力”牌乙酰半胱氨酸泡腾片、“至心砃”牌麝香通心滴丸、“康恩贝”、“宝芝林”、“养营堂”品牌系列保健食品和功能性食品。公司经过逾五十年的发展,已成为国内医药行业的知名企业之一,多年来位居全国制药百强及中药企业排名前列,是国家中药现代化科技产业(浙江)基地示范企业。公司在现代植物药(含中成药)与特色化学药制剂和原料药等领域,实现了从种植、研发、生产到营销的全产业链覆盖,在消化系统、呼吸系统、心脑血管、泌尿系统等中国药品市场最具规模和成长性的治疗领域,形成了较为完善的产品品类布局。报告期内,公司位列“2024年度中国医药工业百强企业”第55位、“2025年度中国非处方药生产企业综合统计榜”第12位、“2025年度中国中成药企业综合竞争力50强”第15名。","listedPrice":8.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康恩贝,600572,康恩贝股票,康恩贝股票老虎,康恩贝股票老虎国际,康恩贝行情,康恩贝股票行情,康恩贝股价,康恩贝股市,康恩贝股票价格,康恩贝股票交易,康恩贝股票购买,康恩贝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}